Company profile
Tevogen Bio Holdings Inc.
NASDAQ: TVGN · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 16DQ —GM —SS 34
v0.1 · 35/100 weight · pillars only
↑ market scale, workforce scale · ↓ return on assets, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.3M
Employees
18
as of 2026-08-21
Market cap
$26.5M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$26.3M-$26.3M2025
Operating income-$26.1M-$26.1M2025
Total assets$4.4M$4.4M2025
Liabilities$12.6M$12.6M2025
Equity-$8.2M-$8.2M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tevogen Bio Holdings Inc.’s financial profile?
Tevogen Bio Holdings Inc. earned -$26.3M in FY2025 net income.
Peers · Healthcare
Sernova Corp.——Sangamo Therapeutics, Inc.——HeartBeam, Inc.——Actuate Therapeutics Inc——NurExone Biologic Inc.——Quantum BioPharma Ltd.——Neighbors
Warren →Key facts
CEORyan H. Saadi
SectorHealthcare
IndustryBiotechnology
HeadquartersWarren, NJ
ExchangeNASDAQ: TVGN
Employees18
IPO date2022-01-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.